Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global 3D Bioprinting Products Market $2.5 Billion by 2029

The global market for 3D bioprinting products market predicted to reach $2.5 billion by 2029, expanding at a double-digit CAGR of 11.1% over the forecast period, driven by cost-effective equipment, wide variety of customization flexibility, and high-end medical technologies worldwide.

  • Recently, the three-dimensional (3D) bioprinting industry has seen plenty of new players, as well as countless new collaborations and innovations.
    • Increasing collaboration between existing players, such as hardware, software and service providers, will lead to optimized and easier-to-integrate product offerings,
      • Recent developments in additive manufacturing have focused on building better, faster, larger and more capable machines and on extending the range of new materials. 
    • Industrial automation in the form of pick-and-place robotics has the potential to drastically raise efficiency by cutting post-production time and costs.
Global 3D Bioprinting Products Market

The 3D printing has rapidly increased in quality and popularity for creation of relatively simple prosthetics, to a silicon prototype of a functioning human heart. 3D printing technology can integrate complex shapes or structures, personalize devices for the user, print samples for faster regulatory approvals for medical industry.

  • The 3D printers have made their way into research labs, universities, and medical offices around the world to create customized products.
    • The 3D printing is now commonly used for anatomical models, personalized surgery, patient-specific implants, bracing and casting, mass customization of medical devices (like hearing-aids), regenerative medicine, and bio-printing.
      • The 3D printing in biomedical applications have garnered much attention as a potentially game-changing technology, for its customized, lifesaving medical interventions.
      • The 3D bioprinting is a promising and innovative biofabrication strategy to precisely position biologics, including living cells and extracellular matrix (ECM) components, in the prescribed 3D hierarchal organization to create artificial multi-cellular tissues/organs. 

While the technology is still in its infancy and the law is untested in many respects, understanding the legal issues is the first step to avoiding potential pitfalls for anyone associated with 3D printing, from designers, to manufactures, to sellers, to consumers. 

  • Due to its versatility, 3D printing has medical applications in medical devices, biologics and drugs regulated by the US Food and Drug Administration (FDA).
  • While a 3D printed prosthetic may be classified as Class I, or low risk, the technology has progressed to enable more advanced implants and tools to be produced that encompass Class III, or high risk, medical devices.
    • The US FDA has released a new draft guidance for medical device manufacturers working with additive manufacturing (AM), which is more commonly known as 3D printing.
3D Printing Medical Devices Market

The global 3D bioprinting medical devices market report provides market size ($million 2019 to 2029), market share, growth trends and forecast (CAGR%, 2023 to 2029). 

The global market for 3D bioprinting segmented by product or application (medical implants, dental implants, orthopedic implants, cranio-maxillofacial implants, bio-engineering, surgical guides, orthopedic surgical guides, dental surgical guides, cranio-maxillofacial surgical guides, surgical instruments); by technology (electron beam melting, laser beam melting, photopolymerization, stereolithography, digital light processing, two-photon polymerization, droplet deposition manufacturing, inkjet printing, fused deposition modeling, multiphase jet solidification); and by raw material (metals, polymers, ceramics, biological cells), and geography.

  • Bioprinting (3D fabrication technology) is used to precisely dispense cell-laden biomaterials for the construction of complex 3D functional living tissues or artificial organs.
    • While still in its early stages, bioprinting strategies have demonstrated their potential use in regenerative medicine to generate a variety of transplantable tissues, including skin, cartilage, and bone.
      • However, current bioprinting approaches still have technical challenges in terms of high-resolution cell deposition, controlled cell distributions, vascularization, and innervation within complex 3D tissues.
  • While no one-size-fits-all approach to bioprinting has emerged, it remains an on-demand, versatile fabrication technique that may address the growing organ shortage as well as provide a high-throughput method for cell patterning at the micrometer scale for broad biomedical engineering applications.
    • Combined with recent advances in human pluripotent stem cell technologies, 3D-bioprinted tissue models could serve as an enabling platform for high-throughput predictive drug screening and more effective regenerative therapies.
  • Market drivers for 3D bioprinting products include
    • By making products that cannot be manufactured in any other way, the technology has the potential to revolutionize the standard of care by addressing previously unmet needs.
    • Companies can perform rapid prototyping to create new designs more quickly and enable faster decision-making; the technology makes it much easier to engage “end users” earlier in the product development process.
    • The custom-made products would reduces waste and scrap materials.
    • More products can be made directly at the point-of-care, possibly accelerating treatment and reducing the number of visits for patients.
      • Hospitals would be able to print skin cells directly onto the patient’s body, including keratinocytes, hair follicles, oil glands and melanocytes.
    • Tissue transplants created from a patient’s own cells would not be rejected, overcoming perhaps the most important issue in the field of transplantation.
    • 3D printed human tissue or organs can be used for drug testing and development purposes.

The global market for 3D bioprinting medical devices research report is divided by geography (regional and country based) into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

The global market for 3D bioprinting devices report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major competitors operating in global market for 3D bioprinting and included in the report are 3D System Corporation, Aspect Biosystems, Biogelx Ltd., BIOLIFE4D, Cellink, Envision TEC GmbH, Eos GmbH Electro Optical Systems, Materialise NV, Nanoscibe GmbH, Organovo Holdings Inc., Prellis Biologics, ROKIT Healthcare Inc., Stsratasys Ltd., and Voxeljet Strategies.

  • Product / Application
    • Medical Implants
      • Dental Implants
      • Orthopedic Implants
      • Cranio-Maxillofacial Implants
    • Bio-engineering
    • Surgical Guides
      • Orthopedic Surgical Guides
      • Dental Surgical Guides
      • Cranio-Maxillofacial Surgical Guides
    • Surgical Instruments
  • Technology
    • Electron Beam Melting
    • Laser Beam Melting
    • Photopolymerization
      • Stereolithography
      • Digital Light Processing
      • Two-photon Polymerization
    • Droplet Deposition Manufacturing
      • Inkjet Printing
      • Fused Deposition Modeling
      • Multiphase Jet Solidification
  • Raw Material
    • Metals
    • Polymers
    • Ceramics
    • Biological Cells
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • 3D System Corporation
    • Aspect Biosystems
    • Biogelx Ltd.
    • Cellink
    • Envision TEC GmbH
    • Eos GmbH Electro Optical Systems
    • Materialise NV
    • Nanoscibe GmbH
    • Organovo Holdings Inc.
    • Prellis Biologics
    • ROKIT Healthcare Inc.
    • Stsratasys Ltd.
    • Voxeljet Strategies

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com